Australia Respiratory Syncytial Virus Market Size, Share, Trends and Forecast by Drug Type, Dosage Form, Treatment Type, Distribution Channel, and Region, 2026-2034

Australia Respiratory Syncytial Virus Market Overview:

The Australia respiratory syncytial virus market size reached USD 30.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 68.03 Million by 2034, exhibiting a growth rate (CAGR) of 9.28% during 2026-2034. The market is driven by the implementation of government-funded RSV immunization programs and national policy initiatives, the introduction of advanced prophylactic RSV vaccines and monoclonal antibodies, and the escalating RSV disease burden with record-high case numbers prompting enhanced public health awareness and intervention strategies. Additionally, the growing recognition of RSV as a significant health threat is expanding the Australia respiratory syncytial virus market share.

Australia Respiratory Syncytial Virus Market Trends:

Government-Funded RSV Immunization Programs and National Policy Implementation

The Australia respiratory syncytial virus market growth is experiencing significant momentum through comprehensive government-funded immunization programs that address RSV prevention across multiple population segments. State and federal authorities are implementing coordinated strategies to reduce the substantial healthcare burden associated with RSV infections, particularly among vulnerable populations including infants, young children, pregnant women, and older adults. Western Australia pioneered this approach by committing AUD 11 million to establish Australia's most inclusive universal nirsevimab program, which commenced in April 2024 and provided coverage to all infants entering their first RSV season along with high-risk children aged 8 to 19 months. Queensland and New South Wales subsequently adopted similar state-managed programs targeting infants and high-risk groups during the 2024 RSV season. These programs demonstrate government commitment to proactive disease prevention, reducing hospitalization rates, alleviating pressure on healthcare systems, and improving health outcomes for the most vulnerable populations. The integration of both maternal vaccination and infant passive immunization strategies reflects a comprehensive public health approach designed to protect infants from birth through their first RSV season when they are most susceptible to severe disease.

Escalating RSV Disease Burden and Enhanced Public Health Awareness

Australia experienced unprecedented RSV activity in 2024, with 175,786 notified cases representing the highest year on record since RSV became a nationally notifiable disease in July 2021, reflecting an average annual increase of 146% since national notification commenced. Nearly half of all cases (49%) occurred in children under four years old, highlighting the substantial pediatric disease burden that drives significant healthcare utilization through hospitalizations, emergency department visits, and intensive care admissions. Among older adults aged 60 years and over, RSV-associated hospitalization rates increased nearly 60-fold from 17 hospitalizations per million population in 2006 to 1,014 hospitalizations per million population in 2022, a dramatic rise largely attributed to increased testing, better diagnostic capabilities, and improved recognition of RSV as a significant pathogen in adult populations. The 2023 data revealed that 90% of RSV-related deaths occurred in individuals aged 60 years and older, underscoring the virus's potential for severe impact on elderly Australians and those with underlying health conditions. These factors contributed to the overall Australia respiratory syncytial virus market growth. Real-world effectiveness data from state immunization programs demonstrated substantial impact, corresponding to fewer infant hospitalizations. This growing disease burden, combined with demonstrable effectiveness of new preventive interventions, has elevated RSV from an underrecognized respiratory pathogen to a prioritized public health target, driving increased awareness among healthcare providers, policymakers, and the general public while supporting expanded access to preventive treatments and vaccines.

Australia Respiratory Syncytial Virus Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on drug type, dosage form, treatment type, and distribution channel.

Drug Type Insights:

• Ribavirin
• Synagis
• Virazole
• Palivizumab
• Riba Tab
• Others

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes ribavirin, Synagis, virazole, palivizumab, Riba Tab, and others.

Dosage Form Insights:

• Oral
• Injectable
• Inhaler
• Others

A detailed breakup and analysis of the market based on the dosage form have also been provided in the report. This includes oral, injectable, inhaler, and others.

Treatment Type Insights:

• Immune Prophylaxis
• Supportive Care
• Antiviral Medications

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes immune prophylaxis, supportive care, and antiviral medications.

Distribution Channel Insights:

• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• Clinics

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, drug stores, retail pharmacies, and clinics.

Regional Insights:

• Australian Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

The report has also provided a comprehensive analysis of all the major regional markets, which include Australian Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, and Western Australia.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Australia Respiratory Syncytial Virus Market News:

• March 2025: Moderna received Australian Therapeutic Goods Administration approval for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus vaccine for adults aged 60 years and older. The approval marked a significant milestone as mRESVIA became the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19. Moderna announced plans to supply mRESVIA from its Melbourne manufacturing facility to protect older Australians vulnerable to RSV complications.
• November 2024: The Australian Government announced that Pfizer's maternal RSV vaccine Abrysvo would be included in the National Immunisation Program starting February 3, 2025, providing free access to all eligible pregnant women between 28 and 36 weeks' gestation. The inclusion followed Abrysvo's TGA registration in March 2024, which authorized its use for active immunization of pregnant women to prevent lower respiratory tract disease caused by RSV in infants from birth through 6 months of age.

Australia Respiratory Syncytial Virus Market Report Coverage:

Key Questions Answered in This Report:

• How has the Australia respiratory syncytial virus market performed so far and how will it perform in the coming years?
• What is the breakup of the Australia respiratory syncytial virus market on the basis of drug type?
• What is the breakup of the Australia respiratory syncytial virus market on the basis of dosage form?
• What is the breakup of the Australia respiratory syncytial virus market on the basis of treatment type?
• What is the breakup of the Australia respiratory syncytial virus market on the basis of distribution channel?
• What is the breakup of the Australia respiratory syncytial virus market on the basis of region?
• What are the various stages in the value chain of the Australia respiratory syncytial virus market?
• What are the key driving factors and challenges in the Australia respiratory syncytial virus market?
• What is the structure of the Australia respiratory syncytial virus market and who are the key players?
• What is the degree of competition in the Australia respiratory syncytial virus market?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Australia respiratory syncytial virus market from 2020-2034.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Australia respiratory syncytial virus market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Australia respiratory syncytial virus industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.